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The COVID-19 pandemic is the most disastrous pneumonia outbreak
to date. Only 3 months after the initial patients were described in the
city of Wuhan in China, hundreds of thousands of confirmed cases have
been reported worldwide. The aim of this manuscript is to assess how
this pandemic can affect the cognitive and neuropsychiatric functions of
multiple sclerosis (MS) patients and to propose preventive measures.
The neuropsychiatric effects of the viral pandemics on general po-
pulation have previously been demonstrated. During the COVID-19
pandemic in China, 53.8% of the 1210 respondents in a cross sectional
study reported to bear moderate to severe psychological impact of the
outbreak. Being a female, a student or having specific physical symp-
toms including coughs, myalgia and chills and a poor self-rated health
status were factors associated with the psychological impact, anxiety
and depression caused by the pandemic (Wang et al., 2020). Another
study showed anxiety and stress disorder rates to be 23% and 27%
respectively among the medical staff of a hospital in China
(Huang et al., 2020).
Patients with MS are specifically vulnerable to the neuropsychiatric
impacts of the COVID-19 pandemic. Variable degrees of cognitive and
neuropsychiatric involvement already exist in MS patients. Cognitive
dysfunction affects up to 70% of MS patients. It can be present even in
the early stages of the disease, and is especially pronounced in the in-
formation processing speed and immediate and episodic memory do-
mains (Oreja-Guevara et al., 2019). Anxiety and depression have been
reported in up to 57% (Butler et al., 2016) and 40% (Feinstein et al.,
2014) of these patients respectively which is highly above the rates in
general population. Depression and anxiety result in a lower quality of
life, increased fatigue and disability scores, and a more aggressive MS
course (Patel et al., 2018). They have been shown to result in disease
exacerbations and decreased treatment adherence in MS patients
(Mohr and Cox, 2001). Additionally, several studies have shown that
anxiety and depression can further impair cognitive function in MS
patients. Depression negatively affects cognition by direct and indirect
mechanisms, through reducing information processing speed and de-
leterious effects on cognitive reserve respectively (Lester et al., 2007).
Researchers have shown that anxiety harms verbal learning in MS pa-
tients, probably through interfering with attention and information
processing speed. They have suggested that treatment of anxiety may
improve cognitive function of MS patients (Vissicchio et al., 2019).
Just as any other member of the society, MS patients are disturbed
by the emotional distress and health anxiety caused by the COVID-19
outbreak. However, patients with MS are known to undertake mala-
daptive coping strategies (Amato et al., 2019) which will make them
even more susceptible to the detrimental neuropsychiatric effects of the
outbreak. Most MS patients are on immunosuppressive or im-
munomodulatory therapies. Patients on immunosuppressive agents are
theoretically at increased risk of being affected by viral pandemics and
a higher level of health anxiety in this group of patients is anticipated.
Moreover, MS patients are losing social support; they have no longer
access to group therapies and cognitive and physical rehabilitation
therapies which could all hypothetically add to the level and stress and
anxiety perceived by these patients.
The impacts of cognitive dysfunction in MS patients are extensive,
hence its treatment have been an area of focus in recent years. Since no
pharmacologic agent has proved significant efficacy in symptomatic
treatment of cognitive dysfunction in MS patients, physicians aim to
undertake preventive strategies for cognitive decline to happen and
progress. This highlights the importance of addressing stress and an-
xiety in MS patients particularly during demanding environmental
conditions such as viral outbreaks.
Considering the rapid worldwide spread of the COVID-19 outbreak,
MS specialists should adapt a strategy to monitor MS patients for
neuropsychiatric complications and also opt for applicable treatment
options. When planning support strategies special attention should be
placed on patients more at risk to develop cognitive and neu-
ropsychiatric complications, including patients with higher level of
disability, those who are taking immunosuppressive therapies, patients
at a progressive stage and patients with comorbid medical conditions.
We suggest monitoring high risk MS patients using easily phone ap-
plicable anxiety scales and to consider therapeutic options including
online support, at home yoga and exercise programs, and antianxiety
medications when needed.
Long term effects of the neuropsychiatric complications of this
pandemic on the cognitive function and disability status of MS patients
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is also a subject for future research.
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